Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan
Sequential ADC therapy with topoisomerase-1-inhibiting payloads is a viable treatment strategy in HER2-low MBC. These results have hypothesis-generating clinical and translational implications. Further studies are needed to better understand ADC cross-resistance as more of these agents enter our clinical armamentarium.
Authors
- Joshua Z. Drago (ORCID: https://orcid.org/0000-0002-7245-1172)
- Maria Bromberg (ORCID: https://orcid.org/0009-0006-9840-7344)
- Pedram Razavi (ORCID: https://orcid.org/0000-0003-4236-0576)
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
- Sarat Chandarlapaty (ORCID: https://orcid.org/0000-0003-4532-8053)
- Nicholas Mai (ORCID: https://orcid.org/0000-0002-1900-7945)
- Emanuela Ferraro (ORCID: https://orcid.org/0000-0001-5863-2391)
- Elaine M. Walsh (ORCID: https://orcid.org/0000-0002-9950-5978)
- Miriam M. Klar (ORCID: https://orcid.org/0000-0001-7609-5470)
- Yuan Chen (ORCID: https://orcid.org/0000-0002-8734-007X)
Institutions
- Maimonides Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1200/po-24-00898
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14